Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Inspire Medical Systems, Inc. (INSP) Shareholders To Inquire About Securities Fraud Class Action

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, inclusive (the “Class Period”). Inspire investors have until January 5, 2026 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR INSPIRE MEDICAL SYSTEMS, INC. (INSP) INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS

What Happened?

On August 4, 2025, Inspire disclosed that the launch of its new sleep apnea device, the Inspire V, was facing an “elongated timeframe” due to several issues, including “many centers [not completing] the training, contracting and onboarding criteria required prior to the purchase and implant of Inspire V,” “software updates for claims submissions and processing” not taking effect until early July, and excess inventory causing poor demand. Further, the Company reduced its 2025 earnings guidance by more than 80%, from $2.20 to $2.30 per share to $0.40 to $0.50 per share.

On this news, Inspire’s stock price fell $42.04, or 32.4%, to close at $87.91 per share on August 5, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) demand for Inspire V was poor, as providers had significant amounts of surplus inventory and were reluctant to transition to a new treatment; (2) Inspire failed to complete training and onboarding for “many” of its treatment center customers; failed to set up basic IT systems, including a customer approval process; failed to ensure that critical insurer claims software was properly updated to facilitate claims processing and payment; and failed to ensure that Medicare reimbursement was in place at the time of the launch; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Inspire common stock during the Class Period, you may move the Court no later than January 5, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [e-mail]
Telephone: [phone],
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251114793000/en/

The Inspire Medical Systems Stock at the time of publication of the news with a fall of -1,77 % to 73,24USD on Tradegate stock exchange (14. November 2025, 17:40 Uhr).